RT Journal Article SR Electronic T1 Diabetes medications and cardiovascular outcome trials: Lessons learned JF Cleveland Clinic Journal of Medicine JO Cleve Clin J Med FD Cleveland Clinic SP 759 OP 767 DO 10.3949/ccjm.84gr.17006 VO 84 IS 10 A1 Kershaw V. Patel A1 Natalia De Albuquerque Rocha A1 Darren K. McGuire YR 2017 UL http://www.ccjm.org/content/84/10/759.abstract AB The US Food and Drug Administration’s current standards require that new diabetes medications demonstrate cardiovascular safety in large, long-term trials. New drugs that have been assessed in such trials are changing the management of type 2 diabetes.